Bleeding Rates and Risk Factors among Cancer and Non-Cancer Patients; A Comparison of Several Anticoagulants

Angelini, Dana E.; Radivoyevitch, T.; McCrae, Keith R.; Khorana, A.A.

doi:10.1016/j.thromres.2018.02.023

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Эти частоты были значительно выше, чем у пациентов с ВТЭО без рака (1,4 и 0,3% соответственно) [36]. В когортном исследовании большой национальной базы данных США обнаружено значимое увеличение частоты кровотечений у онкопациентов с метастатическими формами опухолей при проведении терапии антикоагулянтами по сравнению с пациентами без ЗНО, при этом увеличение частоты кровотечений было характерно для больных, получавших как НМГ, так и ПОАК и антагонисты витамина К (АВК) [37].…”

Section: лечение втэоunclassified

Cancer-associated thrombosis during chemotherapy: treatment and prevention: A review

Koroleva

Kopp

2022

Consilium Medicum

View full text Add to dashboard Cite

Cancer-associated thrombosis is a significant problem today for both oncologists and vascular surgeons. In patients with malignant neoplasms the incidence of symptomatic venous thromboembolism (VTE) is 47 times higher than in the general population. The presence of distant metastases in solid tumors increases the risk of VTE. Most often, VTE develop in pancreatic cancer and stomach cancer. Chemotherapy increases the risk of developing VTE. Low-molecular-weight heparin and direct oral anticoagulants are used for the treatment of VTE in patients with chemotherapy. The results of the СARAVAGGIO study demonstrated that apixaban is not inferior to dalteparin in the treatment of VTE in patients with active cancer and does not increase the risk of bleeding. Before starting chemotherapy, it is necessary to assess the risk of developing VTE using the Khorana risk score. Outpatient patients with high-risk cancer (Khorana score 2 before the start of a new systemic chemotherapy regimen) may be prescribed thromboprophylaxis with low molecular weight heparin. The idea of using direct oral anticoagulants seems promising, but so far it is beyond the scope of approved indications.

show abstract

Section: лечение втэоunclassified

Cancer-associated thrombosis during chemotherapy: treatment and prevention: A review

Koroleva

Kopp

2022

Consilium Medicum

View full text Add to dashboard Cite

show abstract

Prevention and treatment of cancer-associated thrombosis during chemotherapy

Koroleva,

Kopp

2024

jour

View full text Add to dashboard Cite

In patients with malignant neoplasms, the incidence of symptomatic venous thromboembolism (VTE) is 4–7 times higher than in the general population. The presence of distant metastases of solid tumors increases the risk of VTE. Most often, VTE develops in pancreatic and stomach cancers. Chemotherapy increases the risk of VTE development. Low-molecular-weight heparin and direct oral anticoagulants are used for the treatment of VTE in patients receiving chemotherapy.Prior to the start of chemotherapy, it is necessary to assess the risk of VTE development using the Khorana risk score. Outpatient patients with high-risk cancer (Khorana score >3 before the start of a new systemic chemotherapy regimen) may be prescribed thromboprophylaxis.

show abstract

Bleeding Rates and Risk Factors among Cancer and Non-Cancer Patients; A Comparison of Several Anticoagulants

Cited by 2 publications

References 0 publications

Cancer-associated thrombosis during chemotherapy: treatment and prevention: A review

Cancer-associated thrombosis during chemotherapy: treatment and prevention: A review

Prevention and treatment of cancer-associated thrombosis during chemotherapy

Contact Info

Product

Resources

About